Description

Haemonetics Corporation’s $210 Million Cash Flow: Is The Transition Working?

Haemonetics Corporation reported fourth quarter fiscal 2026 revenue of $346 million, marking a 5% increase on a reported basis and 9% organic growth excluding CSL-related impacts. Adjusted earnings per share (EPS) rose 4% year-over-year to $1.29. For the full fiscal year, revenue totaled $1.3 billion with adjusted EPS of $4.96, delivering margin expansion and stronger free cash flow despite $153 million in nonrecurring revenue effects from portfolio transitions. The results highlight the strength of core platforms—particularly plasma and TEG technologies—which underpinned margin improvements and reinforced leadership positions in key markets. The hospital business achieved $160 million in quarterly revenue, growing 8% (7% organically), driven by blood management technologies’ record quarter with 21% revenue growth, partially offset by a 10% decline in interventional technologies (IVT) due to softness in vascular closure and electrophysiology procedure trends.